ArticleBMC cancer2022

Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study.

Shogo Nakamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.